Shots:
- The EC has approved Denbrayce & Izamby, biosimilar versions of Amgen’s Xgeva & Prolia (denosumab) following the CHMP’s recommendation
- Denbrayce prevents skeletal-related events in adults with bone-involved malignancies & treats giant cell tumors of bone in adults & skeletally mature adolescents
- Izamby is indicated to treat osteoporosis in postmenopausal women & men at increased risk of fractures
Ref: PRNewswire | Image: mAbxience | Press Release
Related News:- mAbxience and Abiogen Pharma Enter into a Strategic Licensing Agreement for Biosimilar across Italy
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
